Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis.
Hügle, Boris; Speth, Fabian; Haas, Johannes-Peter.
Pediatr Rheumatol Online J
; 15(1): 16, 2017 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-28288653
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
IL-1 blockade in autoinflammatory syndromes.
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease.
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.
Why not treat human cancer with interleukin-1 blockade?
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
Impact of IL-1 signalling on experimental uveitis and arthritis.
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.